Cart 0

Atlas Antibodies has released novel monoclonal antibodies for female genital tract pathology

Our company has now released new PrecisA Monoclonal antibodies targeting 23 proteins relevant to ovarian cancers, with diagnostic and prognostic values validated in IHC, WB and ICC-IF

September 2022

 

Ovarian cancer is the 8th most common cancer among women and the 5th cause of cancer-related death in women with a 5-year survival of only 30–50%. It still remains the deadliest gynecologic malignancy in the western world and is most often diagnosed at a rarely curable late stage.

Early detection of ovarian cancer would in fact improve the 5-year survival rate, from 20% when the cancer is discovered in stage IV to 90% in stage I.

The primary tumor biopsy followed by immunohistochemical analysis (IHC) of the tissue remains the gold standard to identify the molecular alterations associated with the tumors and identify potential prognostic and predictive biomarkers for early-stage detection.

Atlas Antibodies has now released new PrecisA Monoclonal antibodies targeting 23 proteins relevant to ovarian cancers.

Explore Primary Antibodies for Cancer Research Catalog.